A61K31/721

WATER-ACTIVATED MUCOADHESIVE COMPOSITIONS TO REDUCE INTESTINAL ABSORPTION OF NUTRIENTS

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

TREATMENT OR PREVENTION OF ANAEMIA IN PREGNANT NON-HUMAN MAMMALS

The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

TREATMENT OR PREVENTION OF ANAEMIA IN PREGNANT NON-HUMAN MAMMALS

The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

TREATMENT OR PREVENTION OF ANAEMIA IN PREGNANT NON-HUMAN MAMMALS

The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

THIOL-ENE FUNCTIONALIZED HYDROGELS
20170304453 · 2017-10-26 ·

Disclosed herein are biodegradable hydrogel network containing covalently crosslinked bonds between oligomeric poly(thiol) compounds and oligomeric poly(Michael acceptors). The hydrogels do not substantially change shape upon exposure to aqueous solutions, and as such as suitable for local drug delivery to sensitive tissue areas.

THIOL-ENE FUNCTIONALIZED HYDROGELS
20170304453 · 2017-10-26 ·

Disclosed herein are biodegradable hydrogel network containing covalently crosslinked bonds between oligomeric poly(thiol) compounds and oligomeric poly(Michael acceptors). The hydrogels do not substantially change shape upon exposure to aqueous solutions, and as such as suitable for local drug delivery to sensitive tissue areas.

SLOWLY DIGESTIBLE, SUSTAINED-TYPE ENERGY SUPPLYING AGENT

An object of the present invention is to provide a carbohydrate-derived energy supplying agent having slow digestibility and sustained digestibility functions. According to the present invention, there is provided a slowly digestible, sustained-type energy supplying agent comprising a saccharide composition which satisfies the following (A), (B), (C), and (D): (A) a percentage of α-1,6 bonds relative to all glycosidic bonds is 60% or more; (B) a content of saccharides having a degree of polymerization of 1 and 2 relative to all saccharides is 9 mass % or less; (C) a content of saccharides having a degree of polymerization within a range of 3 to 30 relative to all saccharides is 41 mass % or more; and (D) a content of saccharides having a degree of polymerization of 31 or more relative to all saccharides is 50 mass % or less.

SLOWLY DIGESTIBLE, SUSTAINED-TYPE ENERGY SUPPLYING AGENT

An object of the present invention is to provide a carbohydrate-derived energy supplying agent having slow digestibility and sustained digestibility functions. According to the present invention, there is provided a slowly digestible, sustained-type energy supplying agent comprising a saccharide composition which satisfies the following (A), (B), (C), and (D): (A) a percentage of α-1,6 bonds relative to all glycosidic bonds is 60% or more; (B) a content of saccharides having a degree of polymerization of 1 and 2 relative to all saccharides is 9 mass % or less; (C) a content of saccharides having a degree of polymerization within a range of 3 to 30 relative to all saccharides is 41 mass % or more; and (D) a content of saccharides having a degree of polymerization of 31 or more relative to all saccharides is 50 mass % or less.

Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

TOPICAL COMPOSITION FOR REDUCING PATHOGEN BINDING
20170281660 · 2017-10-05 ·

A method of reducing pathogen binding on skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more prebiotic and at least one carrier.